CN1466953A - Composite preparation for preventing and treating agedness degeneration of macula - Google Patents
Composite preparation for preventing and treating agedness degeneration of macula Download PDFInfo
- Publication number
- CN1466953A CN1466953A CNA03117180XA CN03117180A CN1466953A CN 1466953 A CN1466953 A CN 1466953A CN A03117180X A CNA03117180X A CN A03117180XA CN 03117180 A CN03117180 A CN 03117180A CN 1466953 A CN1466953 A CN 1466953A
- Authority
- CN
- China
- Prior art keywords
- age
- macular degeneration
- vitamin
- related macular
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A composite medicine for preventing and treating senile macula retinae lesion contains VA, VE, VC, Zn, Cu, Xanthophyll and auxiliary material. Its advantages are sure curative effect, and no toxic by-effect.
Description
Technical field
The present invention relates to a kind of medicine, especially a kind of combination drug that is used to prevent, treat age-related macular degeneration.
Background technology
Age-related macular degeneration and cataract are the main causes of old people's inpairment of vision and blinding.Annual nearly 1,900 ten thousand people of China suffer from age-related macular degeneration, and morbidity is sharply risen among the crowd of this kind disease after 65 years old.The factor that causes age-related macular degeneration has a lot, as heredity, patient self ocular disease and hypermetropia, light color look, cardiovascular disease or the like.The common trait of age-related macular degeneration is to occur xanchromatic glass-film wart under the retina, the professional can find it under the mydriatic situation of patient, with regard to the glass-film wart, itself can not cause visual deterioration, but, age-related macular degeneration make the glass-film wart become big and quantity when increasing when making progress to some extent, just can cause serious visual deterioration, in addition blind.Age-related macular degeneration in late period patient is except that having the glass-film wart in addition, also destroyed with the supporting tissue and the photoreceptor cell of central retinal area, perhaps subretinal unusual and fragility blood vessel causes that retina oozes out or symptom such as hemorrhage, and this is the basic reason that causes visual loss.At present, treatment for the age-related macular degeneration in late period is quite limited, the medicine that does not still slow down up to now or prevent the age-related macular degeneration in mid-term to develop to harm, especially improve constantly the current society that the average life that makes people is prolonged in living standard, age-related macular degeneration patient's quantity also will obviously increase, therefore, the medicine of developing and develop effective prophylactic treatment age-related macular degeneration has been to go.
Summary of the invention
The object of the present invention is to provide a kind of having no side effect, and curative effect is reliable, the compound formulation of the energy prophylactic treatment age-related macular degeneration of taking convenience.
Each or each tablet preparation provided by the invention is made by the raw material of following weight portion:
Vitamin A 1600IU-7500IU
Vitamin E 35IU-120IU
Vitamin C 90-120mg
Zinc 14-20mg
Copper 0.3-1.3mg
Phylloxanthin 0.8-1.8mg
Surplus is an adjuvant.
Wherein, vitamin A and vitamin E are fat-soluble liquid.
Described adjuvant is a general adjuvant of making capsule, tablet, oral liquid, as lactose hydras, avicel cellulose, stearic acid, stearic acid magnesium salt, silicon dioxide, sorbitol ester, alkyl citrate, flavochrome, red pigment etc.
The present invention has following advantage and effect: because such scheme, make compound formulation provided by the invention can effectively suppress the age-related macular degeneration in late period of carrying out property, prevent its visual deterioration, can alleviate the development of carrying out property age-related macular degeneration in mid-term, can effectively prevent early stage age-related macular degeneration.Take this compound formulation for a long time, not only convenient, nontoxic, side effect, and can stop the process of age-related macular degeneration, the rescue vision being crossed the life in old age to old people's peace a bright world is provided.
The present invention is through 1640 routine clinical observations, and its result is as follows:
One, diagnostic criteria, the standard and the method that adopt doctor trained in Western medicine that age-related macular degeneration is diagnosed.
Two, material and method:
1. contain zinc preparation, promptly commercially available gluconic acid zinc metal sheet, every contains 10mg zinc, obeys secondary every day, obeys 1 at every turn;
2. antioxidant, promptly commercially available vitamin A grain, every contains dehydroretinol 5000IU, and obey once every day, obeys one at every turn; Commercially available vitamin E grain, every contains vitamin e1 00IU, and obey once every day, obeys one at every turn; Commercially available VITAMIN C TABLET grain, every contains vitamin C 100mg, obeys secondary every day, obeys the 1-2 sheet at every turn;
3. compound formulation of the present invention is obeyed secondary every day, each time sooner or later, each 2-5 grain;
4. placebo, the i.e. sheet made from food starch fully;
Three, physical data, patient 1640 people, wherein the women accounts for 56%, 69 years old mean age, patient's the state of an illness is not from having obvious age-related macular degeneration to late period age-related macular degeneration a glance inpairment of vision and another eye vision is fair, and be divided into 4 classes according to the state of an illness: 1 class promptly is which eye does not all have the glass-film wart for there not being age-related macular degeneration; 2 classes are early stage age-related macular degeneration, promptly a glance or two several little glass-film warts are arranged; 3 classes are the age-related macular degeneration in mid-term, and promptly any a glance all has many medium sized glass-film warts or one or more big glass-film warts are arranged; 4 classes are the age-related macular degeneration in late period, promptly only have a glance to have light sensation cell or center to look supporting tissue and destroy, or retinal vessel unusual (moist) is arranged.Except that age-related macular degeneration, all do not have other oculopathy that jeopardizes eye eyesight among these patients, do not do the medical history of operated eye yet.Each class patient all is divided into four groups at random, and clothes have above-mentioned four kinds of preparations respectively.
Four. the result
1. take patient of the present invention, there is 75% age-related macular degeneration in mid-term patient no longer to be further developed into the age-related macular degeneration in late period, there is 69% age-related macular degeneration in late period patient no longer to further develop, has 85% early stage age-related macular degeneration patient not further develop again to visual loss.
2. take only zinciferous patient, there is 21% age-related macular degeneration in mid-term patient no longer to be further developed into the age-related macular degeneration in late period, there is 11% age-related macular degeneration in late period patient no longer to further develop to visual loss, for early stage age-related macular degeneration patient, still do not alleviate its be further developed in, the process of old phase age-related macular degeneration.
3. take the patient who only contains antioxidant, there is 17% age-related macular degeneration in mid-term patient no longer to be further developed into the age-related macular degeneration in late period, there is 10% age-related macular degeneration in late period patient no longer to further develop to visual loss, for early stage age-related macular degeneration patient, still do not alleviate its be further developed in, the process of old phase age-related macular degeneration.
4. take the patient of placebo, then further develop the dangerous maximum of the state of an illness, do not have any effect.
Five. conclusion
According to clinical observation, be in the high-risk patient of carrying out property age-related macular degeneration in late period, after adhering to taking compound formulation provided by the invention, can effectively prevent its visual deterioration.For the patient of carrying out property age-related macular degeneration in mid-term, adhere to taking compound formulation provided by the invention after, can slow down its pathological changes, the rescue vision.For early stage age-related macular degeneration patient, adhere to taking compound formulation provided by the invention after, can effectively prevent the degeneration of old macula lutea.
The specific embodiment
Embodiment 1
Take off the raw material of row weight portion, make 1000 of complex capsules with processing method, the equipment of prior art:
Vitamin A 1600IU * 1000
Vitamin E 120IU * 1000
Vitamin C 90mg * 1000
Zinc 20mg * 1000
Copper 0.3mg * 1000
Phylloxanthin 1.8mg * 1000
Surplus is the required general adjuvant of preparation capsule.
Embodiment 2
Take off the raw material of row weight portion, make 1000 of complex tablets with processing method, the equipment of prior art:
Vitamin A 7500IU * 1000
Vitamin E 35IU * 1000
Vitamin C 120mg * 1000
Zinc 14mg * 1000
Copper 1.3mg * 1000
Phylloxanthin 0.8mg * 1000
Surplus is the required general adjuvant of preparation tablet.
Embodiment 3
Take off the raw material of row weight portion, make 1000 of complex capsules with processing method, the equipment of prior art:
Vitamin A 4525IU * 1000
Vitamin E 90IU * 1000
Vitamin C 100mg * 1000
Zinc 18mg * 1000
Copper 0.85mg * 1000
Phylloxanthin 1.25mg * 1000
Surplus is the required general adjuvant of preparation capsule.
Claims (3)
1, a kind of compound formulation of prophylactic treatment age-related macular degeneration is characterized in that each or each tablet preparation made by the raw material of following weight portion:
Vitamin A 1600IU-7500IU
Vitamin E 35IU-120IU
Vitamin C 90-120mg
Zinc 14-20mg
Copper 0.3-1.3mg
Phylloxanthin 0.8-1.8mg
Surplus is an adjuvant.
2, compound formulation according to claim 1 is characterized in that described vitamin A and vitamin E are fat-soluble liquid.
3, compound formulation according to claim 1, it is characterized in that described adjuvant is a general adjuvant of making capsule, tablet, oral liquid, as lactose hydras, avicel cellulose, stearic acid, stearic acid magnesium salt, silicon dioxide, sorbitol ester, alkyl citrate, flavochrome, red pigment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA03117180XA CN1466953A (en) | 2003-01-15 | 2003-01-15 | Composite preparation for preventing and treating agedness degeneration of macula |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA03117180XA CN1466953A (en) | 2003-01-15 | 2003-01-15 | Composite preparation for preventing and treating agedness degeneration of macula |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1466953A true CN1466953A (en) | 2004-01-14 |
Family
ID=34152675
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA03117180XA Pending CN1466953A (en) | 2003-01-15 | 2003-01-15 | Composite preparation for preventing and treating agedness degeneration of macula |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1466953A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101142321B (en) * | 2004-11-18 | 2012-06-06 | 耶鲁大学 | Methods and compositions for treating ocular disorders |
| CN111838321A (en) * | 2020-08-18 | 2020-10-30 | 青岛大学 | Senile nutrition bag containing lutein and prebiotics and preparation method thereof |
-
2003
- 2003-01-15 CN CNA03117180XA patent/CN1466953A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101142321B (en) * | 2004-11-18 | 2012-06-06 | 耶鲁大学 | Methods and compositions for treating ocular disorders |
| CN111838321A (en) * | 2020-08-18 | 2020-10-30 | 青岛大学 | Senile nutrition bag containing lutein and prebiotics and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5457135A (en) | Treatment of age related macular degeneration with beta-carotene | |
| CN103566049B (en) | Regard the composition of macular degeneration disease in eyes regarding macular pigment optical density and prevention or treatment age related for improving | |
| DK2729217T3 (en) | METHOD OF IMPROVING GLOSSARY GENERATION | |
| CN103735733B (en) | A kind of compound preparation containing lutein ester and preparation method thereof | |
| US8658624B2 (en) | Pharmaceutical compositions for preventing and treating eye pathologies | |
| CN1535116A (en) | Nutritional supplement to treat macular degeneration | |
| CN101199526A (en) | Improving eyesight guard inspect health care preparation and preparing method thereof | |
| CN1686547A (en) | Long time use compound preparation for treating diabetes | |
| CN102753163B (en) | Composition comprising as active ingredient l-carnitine in combination with hydroxykynurenine-o-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation | |
| WO2005027950A1 (en) | Eye nutritional supplement | |
| CN1466953A (en) | Composite preparation for preventing and treating agedness degeneration of macula | |
| CN105520137A (en) | Healthy food with functions of relieving asthenopia and protecting eyesight | |
| CN1814044A (en) | Capsule or tablet for relieving vision fatigue and preparing method | |
| Kayani et al. | Frequency of retinopathy among diabetics admitted in a teaching hospital of Lahore | |
| EP1853239A1 (en) | Use of zeaxanthin for the treatment of diseases of the peripheral retina | |
| Giusti | Lanthony 15-Hue Desaturated Test for screening of early color vision defects in uncomplicated juvenile diabetes | |
| Hu et al. | Prevention and reversal of galactose cataract in rats with topical Sorbinil. | |
| JPH10167963A (en) | Preparation for treating retinopathy containing lower alkanoyl l-carnitine | |
| RU2489146C1 (en) | Method of treating "dry" form of age-related macular degeneration | |
| Suan et al. | Corneal perforation in patients with vitamin A deficiency in the United States | |
| CN101040893A (en) | Blueberry capsule for protecting vision and the preparing method | |
| CN1915337A (en) | Capsule of eye protector for patient of diabetes | |
| CN101856429B (en) | Medicine compound with visual fatigue relieving function and preparation method thereof | |
| CN1181932A (en) | Berbamine used as medicine for preventing and curing cataract | |
| CA2800186A1 (en) | Nutritional formulations and method for treating diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |